Home > Publications database > EVI1-mediated Programming of Normal and Malignant Hematopoiesis. > print

001     284613
005     20240229155053.0
024 7 _ |a 10.1097/HS9.0000000000000959
|2 doi
024 7 _ |a pmid:37810550
|2 pmid
024 7 _ |a pmc:PMC10553128
|2 pmc
024 7 _ |a altmetric:155259036
|2 altmetric
037 _ _ |a DKFZ-2023-02032
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Lux, Susanne
|0 P:(DE-He78)5b127bc6b2eee08c7aa37c90e72ea340
|b 0
|e First author
|u dkfz
245 _ _ |a EVI1-mediated Programming of Normal and Malignant Hematopoiesis.
260 _ _ |a [Philadelphia, Pennsylvania]
|c 2023
|b Wolters Kluwer Health
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1696923015_20952
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a DKFZ-ZMBH Alliance / #EA:A012#LA:A012#
520 _ _ |a Ecotropic viral integration site 1 (EVI1), encoded at the MECOM locus, is an oncogenic zinc finger transcription factor with diverse roles in normal and malignant cells, most extensively studied in the context of hematopoiesis. EVI1 interacts with other transcription factors in a context-dependent manner and regulates transcription and chromatin remodeling, thereby influencing the proliferation, differentiation, and survival of cells. Interestingly, it can act both as a transcriptional activator as well as a transcriptional repressor. EVI1 is expressed, and fulfills important functions, during the development of different tissues, including the nervous system and hematopoiesis, demonstrating a rigid spatial and temporal expression pattern. However, EVI1 is regularly overexpressed in a variety of cancer entities, including epithelial cancers such as ovarian and pancreatic cancer, as well as in hematologic malignancies like myeloid leukemias. Importantly, EVI1 overexpression is generally associated with a very poor clinical outcome and therapy-resistance. Thus, EVI1 is an interesting candidate to study to improve the prognosis and treatment of high-risk patients with 'EVI1high' hematopoietic malignancies.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Milsom, Michael
|0 P:(DE-He78)7b613cadb8c16ce178713e15b85d982c
|b 1
|e Last author
|u dkfz
773 _ _ |a 10.1097/HS9.0000000000000959
|g Vol. 7, no. 10, p. e959 -
|0 PERI:(DE-600)2922183-3
|n 10
|p e959
|t HemaSphere
|v 7
|y 2023
|x 2572-9241
909 C O |o oai:inrepo02.dkfz.de:284613
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)5b127bc6b2eee08c7aa37c90e72ea340
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)7b613cadb8c16ce178713e15b85d982c
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-06-14T08:57:17Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-06-14T08:57:17Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Double anonymous peer review
|d 2023-06-14T08:57:17Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-09-04
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-09-04
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-09-04
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b HEMASPHERE : 2022
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-27
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b HEMASPHERE : 2022
|d 2023-10-27
920 2 _ |0 I:(DE-He78)A012-20160331
|k A012
|l A012 Experimentelle Hämatologie
|x 0
920 0 _ |0 I:(DE-He78)A012-20160331
|k A012
|l A012 Experimentelle Hämatologie
|x 0
920 1 _ |0 I:(DE-He78)A012-20160331
|k A012
|l A012 Experimentelle Hämatologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A012-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21